Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.74 +1.8%	$1.59	$1.03 ▼ $2.41	$53.35M	-0.53	413,994 shs	122,957 shs
AZRX AzurRx BioPharma	$2.04 +0.5%	$4.04	$3.36 ▼ $26.30	$19.03M	1.51	628,703 shs	163,788 shs
ELYM Eliem Therapeutics	$2.38 +8.7%	$1.48	$2.35 ▼ $11.55	$70.81M	-0.39	486,688 shs	803,871 shs
OSTX OS Therapies	$2.48 +3.3%	$1.83	$1.12 ▼ $7.00	$79.09M	N/A	737,634 shs	1.08 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	+2.96%	-4.40%	+6.10%	-17.92%
AZRX AzurRx BioPharma	+0.49%	+234.43%	+314.95%	+436.98%	+385.71%
ELYM Eliem Therapeutics	+8.68%	+25.26%	+60.81%	+101.69%	-60.86%
OSTX OS Therapies	0.00%	+20.39%	+43.35%	+47.62%	-38.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.4899 of 5 stars	3.5	5.0	0.0	0.0	1.1	0.0	0.6
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.3771 of 5 stars	3.6	0.0	0.0	0.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	158.62% Upside
AZRX AzurRx BioPharma	0.00	N/A	N/A	N/A
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.25	Buy	$18.00	625.81% Upside

Current Analyst Ratings Breakdown

Latest AZRX, OSTX, ELYM, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
AZRX AzurRx BioPharma	N/A	1.33	1.33
ELYM Eliem Therapeutics	N/A	60.41	60.41
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
AZRX AzurRx BioPharma	6.27%
ELYM Eliem Therapeutics	69.76%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
AZRX AzurRx BioPharma	7.30%
ELYM Eliem Therapeutics	4.70%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
OSTX OS Therapies	N/A	31.89 million	N/A	N/A

AZRX, OSTX, ELYM, and ATNM Headlines

Recent News About These Companies

OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral Capital

August 22 at 10:13 AM | marketbeat.com

OS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details Unavailable

August 19, 2025 | gurufocus.com

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

August 19, 2025 | newsfilecorp.comN

Earnings Outlook For OS Therapies

August 18, 2025 | benzinga.com

OS Therapies Updates Quorum Rules for Shareholder Meetings

August 15, 2025 | tipranks.com

OS Therapies Delays Q2 2025 Financial Report

August 15, 2025 | tipranks.com

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14, 2025 | newsfilecorp.comN

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

August 9, 2025 | finance.yahoo.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 7, 2025 | newsfilecorp.comN

OS Therapies files to sell 3.76M shares of common stock for holders

August 6, 2025 | msn.com

OS Therapies Inc News (OSTX) - Investing.com

July 18, 2025 | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZRX, OSTX, ELYM, and ATNM Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.74 +0.03 (+1.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 0.00 (-0.29%)

As of 08/22/2025 07:33 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Eliem Therapeutics NASDAQ:ELYM

$2.38 +0.19 (+8.68%)

As of 08/22/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.43 -0.05 (-2.18%)

As of 08/22/2025 07:31 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time